Leqembi Endorsed for Early Alzheimer's Therapy

The European Medicines Agency's human medicines committee has recommended Leqembi (lecanemab) for treating early Alzheimer's disease in patients with one or no copies of the ApoE4 gene, due to a lower risk of amyloid-related imaging abnormalities (ARIA). This decision follows a re-examination of data showing Leqembi's benefits in slowing cognitive decline outweigh its risks in this restricted population. The recommendation includes safety measures like MRI monitoring and a controlled access programme to mitigate ARIA risks. The decision now awaits approval from the European Commission.